Compare · AZ vs TMO
AZ vs TMO
Side-by-side comparison of A2Z Cust2Mate Solutions Corp. (AZ) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZ and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $174.49B, about 516.1x AZ ($338.1M).
- Over the past year, AZ is up 1.9% and TMO is up 11.5% - TMO leads by 9.6 points.
- Both names hit the wire about 6 times in the past 4 weeks.
- TMO has more recent analyst coverage (25 ratings vs 3 for AZ).
- Company
- A2Z Cust2Mate Solutions Corp.
- Thermo Fisher Scientific Inc
- Price
- $7.58-0.13%
- $469.57+0.63%
- Market cap
- $338.1M
- $174.49B
- 1M return
- +8.75%
- -4.31%
- 1Y return
- +1.88%
- +11.45%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 6
- Recent ratings
- 3
- 25
A2Z Cust2Mate Solutions Corp.
A2Z Smart Technologies Corp. provides services in the field of advanced engineering capabilities to the military/security markets and governmental agencies in Israel. The company produces unmanned remote-controlled vehicles and energy power packs; products for the civilian and retail markets; and fuel tank intelligent containment system, a capsule that can be placed in a fuel tank to prevent gas tank explosions. It also offers retail automation solutions for large grocery stores and supermarkets, as well as offers maintenance and calibration services to external and in-house complex electronic systems and products. A2Z Smart Technologies is headquartered in Vancouver, Canada.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest AZ
- SEC Form F-3 filed by A2Z Cust2Mate Solutions Corp.
- A2Z Cust2Mate Announces Business Updates and Investor Conference Call
- SEC Form SCHEDULE 13G filed by A2Z Cust2Mate Solutions Corp.
- SEC Form 6-K filed by A2Z Cust2Mate Solutions Corp.
- A2Z Receives Notice from Nasdaq Confirming Compliance with Annual Meeting Requirement
- Carrefour Israel and A2Z Cust2Mate to Deploy 4,000 Smart Shopping Carts Nationwide
- A2Z Announces Audited Full-Year 2025 Financial Results
- SEC Form 6-K filed by A2Z Cust2Mate Solutions Corp.
- SEC Form 20-F filed by A2Z Cust2Mate Solutions Corp.
- SEC Form 6-K filed by A2Z Cust2Mate Solutions Corp.
Latest TMO
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Thermo Fisher Scientific Reports First Quarter 2026 Results
- AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
- Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics
- SEC Form DEFA14A filed by Thermo Fisher Scientific Inc
- SEC Form DEF 14A filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 23, 2026
- SEC Form 4 filed by Sperling Scott M
- SEC Form 4 filed by Keith R. Alexandra
- SEC Form 4 filed by Lynch Karen S